These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12546968)

  • 21. The CSD Drug Subset: The Changing Chemistry and Crystallography of Small Molecule Pharmaceuticals.
    Bryant MJ; Black SN; Blade H; Docherty R; Maloney AGP; Taylor SC
    J Pharm Sci; 2019 May; 108(5):1655-1662. PubMed ID: 30615878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
    Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
    Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 970 million druglike small molecules for virtual screening in the chemical universe database GDB-13.
    Blum LC; Reymond JL
    J Am Chem Soc; 2009 Jul; 131(25):8732-3. PubMed ID: 19505099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lead-oriented synthesis: a new opportunity for synthetic chemistry.
    Nadin A; Hattotuwagama C; Churcher I
    Angew Chem Int Ed Engl; 2012 Jan; 51(5):1114-22. PubMed ID: 22271624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In silico techniques for the identification of bioisosteric replacements for drug design.
    Devereux M; Popelier PL
    Curr Top Med Chem; 2010; 10(6):657-68. PubMed ID: 20337588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Facts, figures and trends in lead generation.
    Deprez-Poulain R; Deprez B
    Curr Top Med Chem; 2004; 4(6):569-80. PubMed ID: 14965294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction methods and databases within chemoinformatics: emphasis on drugs and drug candidates.
    Jónsdóttir SO; Jørgensen FS; Brunak S
    Bioinformatics; 2005 May; 21(10):2145-60. PubMed ID: 15713739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strength and honor through the pharmaceutical industry's embrace of green chemistry?
    Fortunak J; Confalone PN; Grosso JA
    Curr Opin Drug Discov Devel; 2007 Nov; 10(6):651-3. PubMed ID: 17987518
    [No Abstract]   [Full Text] [Related]  

  • 29. A screening study of ChirBase molecular database to explore the expanded chiral pool derived from the application of chiral chromatography.
    Piras P; Roussel C
    J Pharm Biomed Anal; 2008 Apr; 46(5):839-47. PubMed ID: 17942261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can we learn to distinguish between "drug-like" and "nondrug-like" molecules?
    Ajay A; Walters WP; Murcko MA
    J Med Chem; 1998 Aug; 41(18):3314-24. PubMed ID: 9719583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toward automated biochemotype annotation for large compound libraries.
    Chen X; Liang Y; Xu J
    Mol Divers; 2006 Aug; 10(3):495-509. PubMed ID: 16967195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of small molecule libraries for NMR screening and other applications in drug discovery.
    Jacoby E; Davies J; Blommers MJ
    Curr Top Med Chem; 2003; 3(1):11-23. PubMed ID: 12570776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?
    Beaumont K; Smith DA
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):61-71. PubMed ID: 19152214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virtual screening: are we there yet?
    Jalaie M; Shanmugasundaram V
    Mini Rev Med Chem; 2006 Oct; 6(10):1159-67. PubMed ID: 17073716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design strategies for building drug-like chemical libraries.
    Mitchell T; Showell GA
    Curr Opin Drug Discov Devel; 2001 May; 4(3):314-8. PubMed ID: 11560064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening.
    Zuegg J; Cooper MA
    Curr Top Med Chem; 2012; 12(14):1500-13. PubMed ID: 22827520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Organic chemistry in drug discovery.
    MacCoss M; Baillie TA
    Science; 2004 Mar; 303(5665):1810-3. PubMed ID: 15031494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reverse pharmacognosy: another way to harness the generosity of nature.
    Blondeau S; Do QT; Scior T; Bernard P; Morin-Allory L
    Curr Pharm Des; 2010 May; 16(15):1682-96. PubMed ID: 20222859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in the development of chiral drugs.
    Caner H; Groner E; Levy L; Agranat I
    Drug Discov Today; 2004 Feb; 9(3):105-10. PubMed ID: 15038394
    [No Abstract]   [Full Text] [Related]  

  • 40. HAD: an automated database tool for analyzing screening hits in drug discovery.
    Shen J
    J Chem Inf Comput Sci; 2003; 43(5):1668-72. PubMed ID: 14502501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.